Biotech Values

[vinmantoo]

gmm,

You are still missing the point. Both drugs are designed to relieve constipation that is derived from taking opiates. Not everyone taking opiates gets constipation. You are postulating that people would prefer or that it is better for people to take a drug that don't need or might not need, rather than only taking the drug if they have a problem with constipation.

You can spin it any way you like, but the NKTR approach is to give drugs to all people who take opiates rather than only those with OIC. While I am sure NKTR would prefer increased usage, I doubt very much that insurance companies like the idea of paying for a drug that patients don't or might not need rather than waiting for a need to arise.